How many Europeans are affected by VKC?

Article

The prevalence of vernal keratoconjunctivitis (VKC) in Europe is 3.2 per 10000 inhabitants, according to a study published in the August 2008 issue of the British Journal of Ophthalmology.

The prevalence of vernal keratoconjunctivitis (VKC) in Europe is 3.2 per 10000 inhabitants, according to a study published in the August 2008 issue of the British Journal of Ophthalmology.

Dominique Brémond-Gignac of the Service d’Ophtalmologie, APHP, Hôpital Robert Debré, Paris, France and colleagues sent a survey to 3003 ophthalmologists across six countries with, cumulatively, 151.9 million inhabitants. The team analyzed the results to extrapolate data for number of VKC cases across the 15 European Union member states (2002). The survey response rate was 29.5% (n=886).

The team estimated 1.16–10.55 inhabitants per 10000 in Western European to be affected by VKC, with 0.30–2.26 per 10000 to be affected by VKC with corneal complications. The prevalence of VKC was found to be lower than expected in most countries questioned, although in Italy the range was 2.4–27.8/10000. However, the ranges for VKC prevalence were 0.7–8.4, 1.2–8.7, 0.6–4.6, 0.7–3.3 and 0.3–1.9 in Finland, Sweden, the Netherlands, France and Norway, respectively. The rate of VKC with corneal complications was 0.4–4.8, 0.3–2.4, 0.2–2.8, 0.2–1.6, 0.3–1.4 and 0.1–1.0 for each of these countries, respectively.

The team concluded that, based on the correlated and extrapolated data, it was most likely that VKC affects 3.2 of every 10000 people in Western Europe, and that the rate of corneal complications with the disease is 0.8 per 10000.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.